These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 10240143)
21. Medico-legal bulletin number 254: Drug package inserts. DeMarco FJ Med Leg Bull; 1974 Jun; 23(6):1-6. PubMed ID: 4846844 [No Abstract] [Full Text] [Related]
22. Mandatory PPIs to begin in 1981; APhA issues strong objections. Small WE Am Pharm; 1980 Nov; NS20(11):10-1. PubMed ID: 7457342 [No Abstract] [Full Text] [Related]
23. Workshop on conflicting guidelines for the use of vaccines. Halsey NA; Hall CB Pediatrics; 1995 Jun; 95(6):938-41. PubMed ID: 7761228 [No Abstract] [Full Text] [Related]
24. FDA proposes that patient package insert program be rescinded. Hospitals; 1982 Feb; 56(4):84. PubMed ID: 7054117 [No Abstract] [Full Text] [Related]
25. Patient package inserts--a good idea gone bad. Kough RH Pa Med; 1978 Jul; 81(7):15-6. PubMed ID: 662407 [No Abstract] [Full Text] [Related]
27. Pediatric priorities: legislative and regulatory initiatives to expand research on the use of medicines in pediatric patients. Labson MS J Health Care Law Policy; 2002; 6(1):34-72. PubMed ID: 15017951 [No Abstract] [Full Text] [Related]
28. Patient package inserts-an industry viewpoint. Waife SO Trans Stud Coll Physicians Phila; 1977 Jul; 45(1):4-7. PubMed ID: 617242 [No Abstract] [Full Text] [Related]
29. Patient package inserts and the pharmacist's responsibility. Fink JL Am J Hosp Pharm; 1979 Feb; 36(2):226-9. PubMed ID: 420215 [TBL] [Abstract][Full Text] [Related]
30. The package insert and the pharmacist's liability. Simonsmeier LM Am J Pharm Sci Support Public Health; 1977; 149(3):82-9. PubMed ID: 596428 [No Abstract] [Full Text] [Related]
31. FDA proposes patient package inserts for most drugs. Mayberger HW; Bell BJ Leg Aspects Med Pract; 1979 Oct; 7(10):42-4. PubMed ID: 263192 [No Abstract] [Full Text] [Related]
33. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer. Goyan JE Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484 [No Abstract] [Full Text] [Related]
34. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
35. Plans to restrict 'extra-label' use of cephalosporins in the USA. Vet Rec; 2012 Feb; 170(6):142. PubMed ID: 22331777 [No Abstract] [Full Text] [Related]
36. Patient package inserts: the patient's right to know. Kruger ID Bull Am Coll Physicians; 1977 Jan; 18(1):18-9. PubMed ID: 10235933 [No Abstract] [Full Text] [Related]
38. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
39. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
40. Patient package inserts: goals versus achievements. Lasagna L Drug Ther; 1982; ():181-9. PubMed ID: 7105992 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]